PILGRIMS
A framework for robots that know when they're wrong, understand why, and fix problems autonomously.
Website: https://usepilgrims.com/
Cover Block
Open sources
| Field | Value |
|---|---|
| Name | PILGRIMS |
| Tagline | A framework for robots that know when they're wrong, understand why, and fix problems autonomously. [usepilgrims.com] |
| Headquarters | Greeley, CO, United States [The Org] |
| Founded | 1946 |
| Stage | Seed |
| Business Model | Hardware + Software |
| Industry | Deeptech |
| Technology | Robotics |
| Growth Profile | Venture Scale |
| Funding Label | Seed |
| Total Disclosed | ~$32,500,000 (reported aggregate from disclosed rounds) [Business Insider, August 2025] [WOWTale, September 2026] [Tracxn, retrieved 2026] |
Links
Open sources
- Website: https://usepilgrims.com/
What an Investor Needs First
Open sources PILGRIMS is building a software framework that helps robots detect failures, diagnose root causes, and execute corrective actions autonomously, a proposition that merits attention because the company is positioning itself around a persistent bottleneck in real-world machine deployment: systems fail in idiosyncratic ways once they leave controlled environments [usepilgrims.com] [PILGRIMS, retrieved 2026]. The founding story is unusually young and still somewhat fragmented in public records, but Jake Adler is consistently identified as the founder, with Business Insider reporting that he started the company after leaving high school in 2022 and Adler's own site stating he became a Thiel Fellow in 2023 [Business Insider, August 2025] [jakeradler.com, retrieved 2026].
The product claim, based primarily on company materials, is that PILGRIMS monitors machine performance, logs errors and fixes in real time, and uses those records so the same mistake does not recur, with the company describing the system as machine-agnostic across robots, sensors, and environments [usepilgrims.com, retrieved 2026]. If that architecture works outside a narrow pilot setting, the differentiation is not a robot itself but a recovery layer for heterogeneous autonomous systems, which is a more scalable software framing than a single-purpose hardware program, though that remains a thesis rather than a verified outcome [usepilgrims.com, retrieved 2026].
The team picture requires care because public sources appear to conflate this company with another business named Pilgrim, but Adler's founder status is well supported, and public profiles also associate Anurag Kedia, Gagandeep Makker, and Juan Barcena with the company in co-founder or operator roles [Crunchbase, retrieved 2026] [Tracxn, retrieved 2026] [LinkedIn, retrieved 2026]. On funding, the cleanest confirmed datapoints are Business Insider's report of a $4.3 million seed round led by Cantos in August 2025 and multiple later reports that the company raised $25 million in September 2026 at a reported $150 million valuation led by Buckley Ventures, although the latter should still be treated as reported rather than fully company-confirmed [Business Insider, August 2025] [WOWTale, September 2026] [AI Weekly, retrieved 2026].
The business model is best understood, on current evidence, as hardware plus software, with the public product framing centered on an autonomous recovery framework rather than a pure services motion [usepilgrims.com, retrieved 2026]. Over the next 12 to 18 months, the key watch items are straightforward: whether the company can show named deployments, whether its machine-agnostic claim holds across different robotic stacks, and whether fundraising momentum converts into repeatable commercial proof rather than remaining a technically interesting story [usepilgrims.com, retrieved 2026] [WOWTale, September 2026].
Reasoned from indirect evidence -- Core product claims rely on company materials, while founder and funding details are partially corroborated by Business Insider, Crunchbase, Tracxn, and secondary 2026 financing reports.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Seed |
| Business Model | Hardware + Software |
| Industry / Vertical | Deeptech |
| Technology Type | Robotics |
| Growth Profile | Venture Scale |
| Funding | Total disclosed approximately $32.5 million |
Inside the Company
PUBLIC
The public record on PILGRIMS is thin, and the first point to establish is simply what the company says it is building. On its website, PILGRIMS describes itself as "the frontier of embodied AI" and says it is developing a framework that helps robots detect failure, diagnose the cause, and recover autonomously across different machines, sensors, and environments [usepilgrims.com]. Crunchbase lists the company as Pilgrim and identifies Anurag Kedia as co-founder and CEO, alongside co-founder Gagandeep Makker [Crunchbase].
Location and founding details are less settled than the product description. The website does not surface a headquarters or legal-entity disclosure in the captured materials [usepilgrims.com]. Crunchbase provides the company profile and funding record used in startup databases, but the available source set for this section does not independently corroborate a formal incorporation date or a state filing trail [Crunchbase].
Chronology is clearer on financing than on corporate formation. Crunchbase shows Pilgrim as an actively funded startup profile, while the company website presents the current product framing around autonomous machine recovery and real-time error logging [Crunchbase] [usepilgrims.com]. Taken together, the public evidence supports a narrow description: a young robotics software company organizing around robot reliability, with basic company metadata still only partially visible in standard public sources [Crunchbase] [usepilgrims.com].
Partially corroborated -- Relies on the company website and Crunchbase, with product positioning confirmed publicly but company formation and headquarters details only partially corroborated.
Under the Hood
MIXED The core claim is straightforward, and ambitious: PILGRIMS says it is building a framework that helps robots recognize failure, diagnose the cause, and recover without waiting for a human operator [usepilgrims.com]. On the company website, the product is described as machine-agnostic software that monitors machine performance, logs errors and fixes in real time, and feeds those fixes back into a learning engine so the same mistake does not recur [usepilgrims.com]. That framing matters because it places the company less in the category of a single-purpose robot application and more in the category of a recovery and reliability layer for deployed autonomous systems, though that broader interpretation remains an inference from the public product language rather than a verified deployment record [usepilgrims.com].
Public evidence on the actual technical surface is still thin. The website lays out an architecture built around monitoring, diagnosing, and solving issues for autonomous systems, but it does not disclose model design, simulation environment, sensor integrations, latency requirements, or whether recovery actions run fully on-device, through a cloud layer, or in some hybrid configuration [usepilgrims.com]. There are also no verified public demos, benchmarks, or third-party case studies in the sourced material for this report, so claims about performance improvement, failure-rate reduction, or fleet learning should be treated as company-stated capability rather than independently corroborated operating results [usepilgrims.com].
The clearest analytical read, on public evidence alone, is that PILGRIMS is trying to solve a real and under-addressed bottleneck in robotics operations: machines fail in edge conditions, and the recovery workflow is usually expensive, manual, and fragmented [usepilgrims.com]. If the company can show that its system generalizes across robot types and environments, the product could sit close to the control plane of real-world autonomy; for now, that remains the central technical diligence question rather than an established fact [usepilgrims.com].
Claim stands unchecked -- This section relies primarily on company website claims, with no independent public benchmark, demo, or third-party technical validation in the sourced material.
Market Research
Open sources This market matters now because the cost of putting autonomous systems into real environments still rises less from perception gains than from brittle operations, a point the company itself centers in its product framing, while adjacent defense and industrial buyers are showing renewed willingness to fund resilience and biosurveillance infrastructure [usepilgrims.com] [Business Insider, August 2025] [WOWTale, September 2026].
The first complication is definitional. The public record around PILGRIMS points in two directions: the company website describes an embodied AI framework for robots that monitor, diagnose, and remediate failures autonomously [usepilgrims.com], while external coverage tied to Jake Adler describes Pilgrim as a defense biotechnology startup with products in trauma care, chemical countermeasures, and biosurveillance [Business Insider, August 2025] [WOWTale, September 2026]. That leaves the addressable market hard to size directly from named third-party research in this section. On the evidence available, the cleaner read is that the company is pursuing a control layer for failure recovery in autonomous machines, with at least some market pull or investor interest from defense and biosecurity-adjacent use cases [usepilgrims.com] [Business Insider, August 2025].
Without a cited third-party TAM for this exact category, the most defensible approach is to map the company against analogous markets rather than force a false precision. The closest analogues surfaced in public sources are embodied AI software for deployed machines, robot fleet operations software, and, if the defense-biotech reporting is directionally accurate, biosurveillance and CBRN response systems used in government and high-risk environments [usepilgrims.com] [Business Insider, August 2025] [WOWTale, September 2026]. That mix suggests a market thesis built less on a single clean software category and more on a wedge into high-consequence deployments where downtime, false positives, or manual intervention carry operational cost.
Public market signals and adjacent demand
The market evidence here is qualitative, but it is still useful. Business Insider's August 2025 reporting tied the company to defense and biotechnology applications, including Kingsfoil, Voyager, and ARGUS, which implies customer interest in systems that operate under field constraints rather than controlled lab conditions [Business Insider, August 2025]. The company website, by contrast, frames the problem as machine-agnostic reliability across robots, sensors, and environments, a broader thesis that would fit warehouses, industrial inspection, defense robotics, and other edge deployments where failures are frequent and varied [usepilgrims.com].
The main demand driver across those adjacent markets is the same: more autonomy creates more exception handling at the edge. If a system can identify that it is failing, diagnose the source, log the event, and recover without waiting for a human operator, buyers can reduce service burden and improve uptime, at least in theory [usepilgrims.com]. In defense and biosecurity settings, the same logic becomes more acute because the tolerance for failed operation is lower and the environments are less standardized, which helps explain why investor interest may cluster there first [Business Insider, August 2025] [WOWTale, September 2026].
| Analogous market lens | What the public record supports | Source basis |
|---|---|---|
| Robot operations and recovery software | Machines fail across heterogeneous hardware, sensors, and environments; PILGRIMS positions itself as the layer that monitors, diagnoses, and resolves issues autonomously | [usepilgrims.com] |
| Defense autonomy infrastructure | External coverage links Pilgrim to defense-oriented products and high-stakes field deployment contexts | [Business Insider, August 2025] [WOWTale, September 2026] |
| Biosurveillance and threat detection systems | ARGUS is described in secondary coverage as a biosurveillance platform for chemical and biological threats | [Business Insider, August 2025] [WOWTale, September 2026] |
The table points to a market thesis that is real but still unsettled in public. The company appears to sit at the intersection of autonomy software and mission-critical detection systems, which broadens the opportunity set but also makes category benchmarking less reliable at this stage.
Regulatory and macro forces
Policy and procurement conditions matter here because the public use cases are not purely commercial. If the defense-biotech reporting is accurate, then some of the company's perceived opportunity depends on government demand for preparedness, force protection, and domestic biosurveillance capacity, all of which have seen elevated attention since the pandemic period and amid broader defense modernization efforts [Business Insider, August 2025] [WOWTale, September 2026]. That can create large contracts and durable budgets, but it also introduces long sales cycles, validation burdens, and dependence on agency adoption.
There is also a simpler macro force in the robotics reading of the business. As more machines move from pilots into live operations, buyers need software that handles edge-case failure without bespoke engineering for every installation [usepilgrims.com]. The substitute, which is heavier human oversight or service-intensive deployments, becomes less attractive as fleets grow. That tailwind is plausible, but the public evidence here supports the existence of the pain point more clearly than the size or pace of budget conversion.
Claim stands unchecked -- This section relies on company website claims for the core market framing and a limited set of secondary reports for adjacent defense and biosurveillance demand signals; no independent third-party market sizing report for the exact category was confirmed in the available sources.
Competition and Substitutes
MIXED
PILGRIMS appears to be positioning itself less as a robot OEM and more as a recovery layer for autonomous systems, which places it against a mix of incumbents in industrial automation, younger embodied-AI software stacks, and simple in-house troubleshooting workflows rather than a single clean peer set [usepilgrims.com] [Business Insider, August 2025].
The competitive map is fragmented because the company describes a broad horizontal function, monitoring machine performance, diagnosing failures, and applying fixes across different robots and environments, while public reporting around Jake Adler points to a separate defense-biotech Pilgrim with products such as Kingsfoil, Voyager, and ARGUS [usepilgrims.com] [Business Insider, August 2025] [WOWTale, September 2026]. On the embodied-AI reading, the closest competitive buckets are established automation vendors that already sit in robot operations, specialist autonomy software providers, and internal engineering teams that build issue detection and remediation tools for a single fleet. On the defense-biotech reading, the relevant alternatives shift almost completely, toward biosurveillance, protective countermeasures, and battlefield medical suppliers, which is a different market structure altogether [Business Insider, August 2025] [WOWTale, September 2026]. That identity ambiguity is itself a competitive fact, because it makes external benchmarking difficult and weakens confidence in any claim of category leadership.
Where PILGRIMS has a plausible edge today is in the ambition of the product architecture the website describes: machine-agnostic recovery, real-time error logging, and a learning engine intended to prevent repeat failures across deployments [usepilgrims.com]. If that architecture works as described, the edge would come from operational data and feedback loops rather than from the model layer alone. That could become durable if the company accumulates proprietary failure-and-fix histories across many machines and environments, since those logs are hard for a new entrant to recreate quickly. The problem is that this edge is still company-described in the public record, with no independently verified customers, deployments, or ecosystem partnerships attached to the robotics framework itself [usepilgrims.com].
The company is most exposed where distribution and proof matter more than architecture. Large incumbents in industrial automation and robotics software already control service channels, installed fleets, and integration points, which means a horizontal recovery layer must either slot cleanly into those systems or win greenfield deployments one by one. PILGRIMS also does not appear, from the public record available here, to own a privileged procurement channel, a named enterprise customer base, or a standards position that would keep adjacent vendors from building similar monitoring and remediation features into their own stacks [usepilgrims.com] [Crunchbase]. The separate set of reports that frame Pilgrim as a defense-biotech company raises a second exposure: if investors and customers are actually tracking that business instead, then the embodied-AI narrative may be competing not only with rivals but with basic market clarity about what the company is [WOWTale, September 2026] [Business Insider, August 2025].
The most plausible 18-month scenario is that the field sorts first by distribution rather than by technical elegance. Winner if X: a large incumbent automation platform, unnamed in the current source set, if buyers continue to prefer bundled monitoring and support over adding an independent recovery framework. Loser if Y: PILGRIMS, if it cannot translate the website's technical promise into public deployment evidence and a stable category definition. The reverse case is still possible. If the company can show that its error logs and remediation engine generalize across heterogeneous machines, then internal tooling teams are the most likely losers, because their single-fleet systems do not compound learning across environments in the same way the company claims its framework can [usepilgrims.com].
com] [Business Insider, August 2025] [WOWTale, September 2026].
Opportunity
PUBLIC The prize here is large if PILGRIMS can become the software layer that keeps robots operating through failure, because uptime sits at the center of whether autonomous systems move from pilots into real deployment [usepilgrims.com] [Business Insider, August 2025].
The headline opportunity is not simply another robotics tool. It is the chance to become default recovery infrastructure for deployed machines, a layer that monitors performance, diagnoses faults, logs fixes, and feeds those fixes back into a learning engine so the same error does not recur [usepilgrims.com]. That is a meaningful wedge because the company is describing a problem that exists across robot types and environments, not a single-purpose application, and its own materials repeatedly frame the product as machine-agnostic [usepilgrims.com]. The reachability case is still early, but it is not purely aspirational: the company has attracted seed backing from investors including Cantos, Thiel Capital, and reportedly Buckley Ventures, and public reporting ties that financing to a founder who has already drawn attention as a Thiel Fellow, which usually expands access to technical talent and early design partners [Business Insider, August 2025] [WOWTale, September 2026] [jakeradler.com, retrieved 2026].
A few upside paths stand out from the public record, even if none is yet proven.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Recovery layer for field robotics | PILGRIMS becomes the control and remediation layer used by operators that cannot tolerate repeated machine failure in the field | A first visible deployment or partnership in a high-stakes operating environment | The product is presented as monitoring, diagnosing, and solving issues autonomously across machines and environments, which fits field robotics where manual intervention is costly [usepilgrims.com] |
| Embedded reliability stack for OEMs | Robot makers integrate PILGRIMS at the platform level so fixes and logs travel with each deployment | An OEM integration that turns the framework from add-on software into standard equipment | The company's own architecture pitch is machine-agnostic, and every logged fix feeding a learning engine is more valuable when applied across a fleet rather than a single machine [usepilgrims.com] |
| Data moat in autonomous recovery | The company builds a differentiated error-and-remediation dataset that improves recovery performance over time and becomes hard to replicate | Sufficient fleet volume to turn error logging into a reusable knowledge base | PILGRIMS states that every fix is logged and processed so the same mistake does not happen twice, which, if borne out in production, is the clearest path to defensibility in a software layer above heterogeneous hardware [usepilgrims.com] |
The compounding mechanism is straightforward in theory. Each deployed machine creates more failure data, each logged remediation improves the learning engine, and each improvement should reduce the human support burden for the next customer [usepilgrims.com]. In categories where deployment breaks on long-tail edge cases rather than headline model quality, that kind of feedback loop can matter more than raw model performance. The evidence that compounding has started is still thin in public, but the company is at least explicit that logging and learning from fixes sits at the center of the architecture, which is the right primitive if the goal is cross-environment adaptation rather than one-off consulting [usepilgrims.com].
The size of the win is harder to anchor because no public market-sizing study or clean public comparable appears in the source set. Even so, the reported September 2026 financing at a $150 million valuation offers one concrete marker for how early investors are already underwriting the upside [WOWTale, September 2026] [AI Weekly] [Dealroom News]. If the company proves that its recovery layer can travel across robot categories and become embedded in deployments at scale, it could justify an outcome many multiples above that private mark, potentially in the billion-dollar range (scenario, not a forecast), because the value would sit in software control over machine uptime rather than in a single hardware program [usepilgrims.com] [WOWTale, September 2026]. That is still a conditional case, but it is a legible one: own the failure-recovery layer, and the company can capture a strategic position upstream of broader robotics adoption.
Partially corroborated -- Product architecture claims are company-sourced, while funding and founder-background points are partially corroborated by Business Insider, WOWTale, and founder materials.
Sources
Open sources
[usepilgrims.com] PILGRIMS | https://usepilgrims.com/
[Business Insider, August 2025] Pilgrim’s Jake Adler Secures $4.3 Million by Demoing … | https://www.businessinsider.com/pilgrim-jake-adler-4-million-funding-biotech-product-bold-video-2025-8
[WOWTale, September 2026] Defense Biotech Pilgrim Raises $25M Seed at $150M Valuation | https://en.wowtale.net/2026/09/28/235250/
[Tracxn, retrieved 2026] Pilgrim - 2026 Company Profile, Team, Funding, Competitors & Financials | https://tracxn.com/d/companies/pilgrim/__E07z1FauxS065CG7fvDMqwBjI6Bx_3KgKfoNYsWbn48#founders-and-board-of-directors
[The Org, retrieved 2026] Pilgrim's - HQ | https://theorg.com/org/pilgrims/offices/hq
[Crunchbase, retrieved 2026] Pilgrim - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/pilgrim-3433
[LinkedIn, retrieved 2026] Gagandeep M. - Pilgrim | LinkedIn | https://www.linkedin.com/in/gaganmakker/
[jakeradler.com, retrieved 2026] Jake Adler | https://jakeradler.com/
Articles about PILGRIMS
- A Thiel Fellow's Defense Biotech Startup Raises $25 Million for Biosurveillance — The startup, founded by Thiel Fellow Jake Adler, is developing a portable genomic sequencer to spot chemical and biological threats, reportedly with an initial CDC deployment.